19:11 , May 19, 2017 |  BC Week In Review  |  Company News

EC opens investigation into Aspen's EU pricing practices

The European Commission began a formal investigation of Aspen Pharmacare Holdings Ltd. (JSE:APN) amid concerns that the company breached EU antitrust rules by excessively raising the prices of five off-patent cancer medicines: chlorambucil, melphalan, mercaptopurine,...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

GlaxoSmithKline, Aspen deal

The partners terminated a 2009 deal to co-commercialize their product portfolios in sub-Saharan Africa, excluding South Africa, where Aspen received marketing rights to GlaxoSmithKline’s products. The South Africa agreement remains in place, and both companies...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

GlaxoSmithKline, Aspen deal

Aspen exercised an option to acquire GlaxoSmithKline’s thrombosis portfolio in China, including Hong Kong and Macau, India and Pakistan -- the remaining markets not covered under the partners’ 2013 deal. Aspen will now have worldwide...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Aspen deal

AstraZeneca granted Aspen exclusive rights to commercialize AZ’s anesthetics portfolio outside the U.S. The portfolio consists of seven drugs, including general anesthetic Diprivan propofol. AZ will manufacture and supply the products for 10 years. The...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Aspen, Endo deal

Endo’s Litha Pharma Pty. Ltd. subsidiary completed its purchase from Aspen of a portfolio of branded and generic injectable and established products for pain, anti-infectives, cardiovascular and other specialty indications (see BioCentury, July 13). Aspen...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Aspen, Endo deal

Endo’s Litha Pharma Pty. Ltd. subsidiary will purchase from Aspen a portfolio of branded and generic injectable and established products for pain, anti-infectives, cardiovascular and other specialty indications. The portfolio had revenues of $28 million...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

PL37: Phase IIa started

Pharmaleads began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 200 mg oral PL37 thrice daily plus pregabalin or gabapentin for 4 weeks in 108 patients previously treated with pregabalin or gabapentin. Pharmaleads S.A.S....
07:00 , Apr 20, 2015 |  BioCentury  |  Emerging Company Profile

East by South

Nuance Biotech Inc. plans to in-license rights to develop and commercialize assets in China, with a twist on the standard model: it will include clinical trial sites in South Africa to improve the speed and...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Cardiome, Aspen deal

Cardiome granted Aspen exclusive rights to commercialize Cardiome’s IV Brinavess vernakalant in South Africa. The mixed ion channel antagonist is approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Iroko, Aspen deal

Iroko's Iroko Pharmaceuticals Inc. affiliate granted Aspen's Aspen Pharmacare Australia Pty. Ltd. subsidiary exclusive rights to develop and commercialize Zorvolex submicron diclofenac in Australia and New Zealand. Aspen will be responsible for regulatory and pricing...